<DOC>
	<DOCNO>NCT00937066</DOCNO>
	<brief_summary>This study economic evaluation Symbicort ( Budesonide/formoterol ) maintenance reliever therapy ( SMART ) versus competitive alternative . The aim study : - To estimate relative effectiveness one alternative management patient moderate severe asthma systematic review follow outcome : - Cumulative incidence asthma severe exacerbation symptoms - Safety alternative ( frequency adverse event complication due medication ) - To estimate direct medical cost treat pharmacologic alternative : Symbicort SMART versus increase use inhaled corticosteroid Adding long-acting inhale beta 2 agonist plus inhaled corticosteroid . - To create decision analysis model ( decision tree ) allow comparison alternative expect value cost . - To calculate average incremental cost-effectiveness ratio . - To carry sensitivity analysis test de robustness cost-effectiveness result allow reasonable change expect value cost .</brief_summary>
	<brief_title>Cost-effectiveness Study Symbicort Maintenance Reliever Therapy ( SMART )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Moderate severe asthma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Cost-effectiveness analysis</keyword>
	<keyword>Symbicort</keyword>
</DOC>